KLF5 inhibition potentiates anti-PD1 efficacy by enhancing CD8⁺ T-cell-dependent antitumor immunity

Abstract

Background: Immune checkpoint blockers (ICBs) are revolutionized therapeutic strategies for cancer, but most patients with solid neoplasms remain resistant to ICBs, partly because of the difficulty in reversing the highly immunosuppressive tumor microenvironment (TME). Exploring the strategies for tumor immunotherapy is highly dependent on the discovery of molecular mechanisms of tumor immune escape and potential therapeutic target. Krüppel-like Factor 5 (KLF5) is a cell-intrinsic oncogene to promote tumorigenesis. However, the cell-extrinsic effects of KLF5 on suppressing the immune response to cancer remain unclear. Methods:We analyzed the immunosuppressive role of KLF5 in mice models transplanted with KLF5-deleted/overexpressing tumor cells. We performed RNA sequencing, immunohistochemistry, western blotting, real time-PCR, ELISA, luciferase assay, chromatin immunoprecipitation (ChIP), and flow cytometry to demonstrate the effects of KLF5 on CD8 + T cell infiltration and related molecular mechanism. Single-cell RNA sequencing and spatial transcriptomics analysis were applied to further decipher the association between KLF5 expression and infiltrating immune cells. The efficacy of KLF5/COX2 inhibitors combined with anti-programmed cell death protein 1 (anti-PD1) therapy were explored in pre-clinical models. Finally, a gene-expression signature depending on KLF5/COX2 axis and associated immune markers was created to predict patient survival.KLF5 is associated with an immune-supportive TME. Finally, we generate a KLF5/COX2-associated immune score (KC-IS) to predict patient survival. Conclusions:Our results identified a novel mechanism responsible for KLF5-mediated immunosuppression in TME, and targeting the KLF5/COX2/PGE2 axis is a critical immunotherapy sensitizer.

Oncometabolite 2-hydroxyglutarate regulates anti-tumor immunity

“…Various strategies aim to enhance antitumor immunity by targeting immune cells [ 105 , 106 ]. The accumulation of specific metabolites, such as lactate and succinate, in the tumor microenvironment may have an impact on immune components, thus potentially disrupting anti-tumor immunity [ 107 ].…”

BRD4-specific PROTAC inhibits basal-like breast cancer partially through downregulating KLF5 expression

“…We previously reported that FZU0004 [43] and the chemotherapeutic drugs EPI and PTX [44] inhibit KLF5 expression through different mechanisms. We wondered whether 6b, in combination with these compounds, would better inhibit BLBC.…”

Integration of liquid biopsy and immunotherapy: opening a new era in colorectal cancer treatment

“…Flow cytometry can analyze various indicators such as T-cell subgroups, functional status, and expression of immune checkpoint molecules in blood samples. It can aid in evaluating a patient's immune status and predicting the response to immune therapy (131)(132)(133)(134)(135).…”